



UNDERSTANDING ALZHEIMER'S – FROM DISCOVERY RESEARCH TO PATIENT TREATMENT

Sydney, 7 October 2015: Scientists are making important new advancements in the understanding of Alzheimer's disease, one of the biggest health issues of our time. Leading experts will gather at a symposium in Sydney on Monday October 12 to discuss the latest developments including drug discovery and the advancements in clinical data that are driving renewed interest in the sector. The event, hosted by Actinogen Medical, will also feature a patient's perspective on treatment for the disease.

International keynote speaker, Professor Craig Ritchie, Professor of Psychiatry of Aging at Edinburgh University, a global expert in Alzheimer's research, will be presenting some of the latest encouraging developments in treating the disease.

He will be joined by Dr Bryce Vissel from the Garvan Institute to highlight important new basic research discoveries and speakers from Eli Lilly and Alzheimer's Australia to provide a better understanding of Alzheimer's disease, its treatment and the impact on patients.

Finding a new and effective treatment for Alzheimer's disease has never been more important. It is already the second leading cause of death in Australia with 350,000 sufferers; and the number of people diagnosed with Alzheimer's is forecast to double within the next 20 years. Current available therapies have limited benefit and new medicines are desperately needed.

The symposium: *Understanding Alzheimer's – from discovery research to patient treatment* will be held at the Sofitel Hotel in Sydney from 4.30pm. The symposium will be followed by an opportunity to network and meet the speakers over cocktails and canapes.

Full details of the event are as follows:

Date: Monday, 12 October 2015

Time: 4:30 PM-7:00 PM

Place: Sofitel Sydney Wentworth: 61-101 Phillip Street, Sydney NSW 2000

RSVP: amurphy@buchanwe.com.au or (02) 9237 2804

The speakers include:

- Dr Bryce Vissel, Lab Head - Neurodegenerative Diseases, Garvan Institute of Medical Research - Alzheimer's basic research drug discovery
- Professor Craig Ritchie, Psychiatry of Ageing, University of Edinburgh - Alzheimer's clinical research and drug development
- Dr Katarina Kelin, Medical Director of Neuroscience, Eli Lilly (NYSE: LLY) - Commercialising Alzheimer's drugs and the state of play in the markets

- Patient advocate, Alzheimer's Australia - A patient's perspective on Alzheimer's disease and treatment
- Dr Bill Ketelbey, CEO, Actinogen Medical (ASX:ACW) - An overview of Actinogen Medical and the development of its lead drug, Xanamem™

ENDS

Actinogen Medical

Dr Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multi-billion dollar market potential. The cost of Alzheimer's treatment in the US alone was estimated to be US\$250bn in 2013, with this cost estimated to increase to US\$1 trillion by 2050, outstripping the cost of treating all other diseases. Alzheimer's disease is now the second leading cause of death in Australia behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from existing Alzheimer's treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.

About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer's disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer's disease. The Company plans to undertake a Phase II study in mild Alzheimer's patients in 2016.